Figure 4.

The effect of tumor size on the ability of FA-TLR7-1A to enhance anti-CD19 CAR T cell therapy of solid 4T1-mCD19 tumors. Analysis of tumor size and body weight change of mice in which treatments started when the average tumor sizes reached (A) 50 mm³, (B) 90 mm³, and (C) 130 mm³. (D) Comparison of the relative tumor sizes on day 26 after initiation of therapy. The number of mice per treatment group were as follows: for mice with 50mm³ tumors: “No treatment”, n=5; “3 nmol FA-TLR7-1A, 5W”, n=6; “CAR T+PBS”, n=6; “CAR T+3n mol FA-TLR7-1A, 5W”, n=9. For mice with either 90mm³ or 130mm³, n=5 for all the groups. Mean ± SEM. Statistical significance between multiple groups was determined using a 1-way ANOVA followed by a Tukey post hoc analysis. Statistical significance between two groups was determined using an unpaired two‐tailed t‐test (*P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001, ns, not significant P ≥ 0.05).